Dana-Farber Cancer Institute and Clinical.ly Join Forces
Dana-Farber Cancer Institute Teams Up with Clinical.ly
The Dana-Farber Cancer Institute, recognized globally for its excellence in cancer treatment and research, has entered a partnership with Clinical.ly to improve regulatory operations through its Research Suite™. This collaboration is a significant milestone aimed at refining the processes involved in managing clinical trials.
Streamlining Clinical Trial Management
By adopting Clinical.ly's innovative eReg platform, Dana-Farber is taking a key step towards enhancing its clinical trial management operations. This comprehensive, paperless solution is designed to centralize regulatory workflows, ensuring both compliance and transparency in clinical trials. With a growing number of research organizations utilizing Clinical.ly's tools, Dana-Farber is at the forefront of this positive transformation.
A Game Changer for Clinical Research
Clinical.ly's CEO, Henry Kravchenko, expressed excitement about supporting Dana-Farber's clinical research operations, stating, "We are thrilled to support Dana-Farber's clinical research operations. Our eReg platform, along with additional features in Clinical.ly Research Suite™, will empower this renowned organization, and we anticipate positive outcomes for their teams." This partnership signifies a commitment to utilizing state-of-the-art tools for enhanced clinical research efficiency.
Advancements in Clinical.ly Research Suite™
Clinical.ly Research Suite™ is tailored to modernize and streamline the functionalities of clinical trials. By automating essential workflows, this suite not only promotes efficiency but also ensures superior oversight and document management. The components of the Clinical.ly Research Suite™ include:
- eReg: A top-tier electronic regulatory binder.
- eSource: A powerful data capture solution that simplifies data collection.
- eConsent: A digital solution for capturing informed consent, enhancing participant engagement and compliance.
- ClinicallySign: Compliant eSignature functionality in line with regulations.
- ClinicallyPay: A secure solution for participant payments and reimbursements.
About Dana-Farber Cancer Institute
Founded in 1947, Dana-Farber's mission is to provide high-quality treatment for adults and children, while also pursuing groundbreaking research aimed at discovering new cures. As a teaching affiliate of Harvard Medical School, Dana-Farber is consistently ranked among the world's leading cancer hospitals, committed to advancing knowledge and techniques in cancer care.
About Clinical.ly
Clinical.ly specializes in delivering advanced cloud-native technology solutions tailored to the clinical research sector. Their commitment lies in developing technologies that streamline processes, minimizing tedious administrative tasks and allowing clinical research professionals to prioritize patient care. Through innovative solutions, Clinical.ly enhances the efficiency of research organizations and enhances the overall quality of clinical trials.
Frequently Asked Questions
What is the primary purpose of the partnership between Dana-Farber and Clinical.ly?
The partnership aims to enhance regulatory operations and streamline clinical trial management through Clinical.ly's Research Suite™.
What does Clinical.ly's eReg platform offer?
It provides a comprehensive, paperless solution that centralizes regulatory workflows, improving compliance and transparency in clinical trials.
How long has Dana-Farber Cancer Institute been in operation?
Dana-Farber was founded in 1947 and has been a leader in cancer treatment and research since then.
What key components are included in Clinical.ly Research Suite™?
The suite includes eReg, eSource, eConsent, ClinicallySign, and ClinicallyPay, all targeted at improving clinical trial operations.
What is Clinical.ly's commitment to the clinical research industry?
Clinical.ly is dedicated to developing technology that eliminates tedious tasks, allowing clinical research professionals to concentrate on patient care and improve overall research efficiency.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.